Hormonal treatment of visceral disease in breast cancer – pro
Traditionally, hormonal treatment is not recommended in visceral metastatic disease, however, there is more recently more willingness to stay with hormonal therapy in visceral disease. 1. Fulvestrant and exemestane demonstrated clinical benefit in 29.1% and 27.2% of patients with VM, respectively. Median duration of response was 13.5 vs 10.8 months and median duration of clinical benefit was 9.9 vs 8.1 months, respectively.2
1.Campos SM, Guastalla JP, Subar M, et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009; 9:39.
2.Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009; 117:69.
3. NCCN, Breast Cacner 2016
4.Faslodex, Prescribing INformation 2016.